- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Johnson & Johnson to merge with Alza
Johnson & Johnson, New Brunswick, NJ, and Mountain View, CA-based Alza Corp. announced that they have entered into an agreement under which Johnson & Johnson will merge with Alza in a stock-for-stock exchange, valued at roughly $10.5 billion.
Johnson & Johnson, New Brunswick, NJ, and Mountain View, CA-based Alza Corp. announced that they have entered into an agreement under which Johnson & Johnson will merge with Alza in a stock-for-stock exchange, valued at roughly $10.5 billion.
The boards of directors of Johnson & Johnson and Alza have approved the merger, which is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and the European Union merger control regulation, as well as other customary closing conditions. The agreement will also require the approval of Alza's shareholders.
"As a world leader in drug delivery technologies, Alza will bring us significant new product opportunities and will enable us to extend product life cycles," said William C. Weldon, a vice chairman of Johnson & Johnson. "Products and technologies from Alza will enhance existing Johnson & Johnson growth platforms in areas that include oncology, women's health, urology, pain management and the central nervous system." According to Weldon, Alza will retain its name and management as a free-standing Johnson & Johnson company, and will continue to develop new products based on proprietary drug delivery technologies for its other pharmaceutical customers.
"Becoming part of Johnson & Johnson will benefit all of our key audiences - including patients, shareholders, customers and employees," said Ernest Mario, chairman of the board and chief executive officer of Alza. "The merger will enable our shareholders to gain significant value through ownership of Johnson & Johnson shares. This merger will enable our products to reach more patients worldwide, and will allow for the application of advanced drug delivery technologies to a broader spectrum of new and existing pharmaceutical products. Our employees will benefit from the advantages that Johnson & Johnson, a large, highly successful corporation, can provide to enhance their personal and professional growth."
The transaction is expected to close by the early part of the third quarter of 2001. PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Seeking Sustainable Solutions: Can Passion and Profit Coexist in Pharma ESG Efforts?
October 15th 2024Industry leaders gather to discuss different ways life sciences organizations can champion their environmentally-conscious younger employees while combatting still-entrenched public mistrust.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
